At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 44 enrolled
Drug / intervention
122-0551 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-Blind, Randomized, Single Center, Vehicle-Controlled, Parallel Group Study to Determine the Efficacy and Safety of 122-0551 in Subjects With Plaque Psoriasis Receiving Two Weeks of Treatment
In Brief
A Phase 2 clinical trial evaluating 122-0551 and Vehicle for Psoriasis and Plaque Psoriasis. Completed, enrolled 44 participants across 2 sites.
Detailed Summary
Corticosteroids are one of the mainstays of treatment for subjects with corticosteroid-responsive dermatoses such as psoriasis. This study has been designed to determine and compare the efficacy and safety of a formulation of 122-0551 versus the corresponding Vehicle in subjects with stable plaque psoriasis after twice daily dosing for 14 consecutive days.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis, Plaque Psoriasis
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartMay 2012
Primary CompletionSep 2012
First PostedOct 2012
Study CompletionMar 2013
TodayJul 2026
First PostedOct 4, 2012
Enrollment StartMay 1, 2012
Primary CompletionSep 1, 2012
Study CompletionMar 1, 2013
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 13.7 years ago
Interventions
122-0551drug
Applied twice daily for two weeks
Vehicledrug
Applied twice daily for two weeks